Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486809 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT02486809 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 176 participants.
The verdict
NCT02486809, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab administered SC as a single injection via PFS-NSD.
Interventions
- DRUG Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02486809
The ClinicalTrials.gov registry entry for NCT02486809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT02486809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02486809 about?
NCT02486809 is a clinical study titled "A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)". This study will assess the bioequivalence in healthy participants between a high-concentration formulation of lebrikizumab withdrawn from a vial and administered SC as a single injection by a needle and syringe, and a low-concentration formulation of lebrikizumab administered SC as a single injectio...
What is the current status of trial NCT02486809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2015-07. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02486809?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT02486809?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.